NanoViricides Company Insiders
| NNVC Stock | USD 1.14 0.02 1.79% |
NanoViricides employs about 7 people. The company is managed by 11 executives with a total tenure of roughly 77 years, averaging almost 7.0 years of service per executive, having 0.64 employees per reported executive. Evaluation of NanoViricides' management performance can provide insight into the firm performance.
| Irach Taraporewala CEO CEO |
| Eugene Seymour CEO CEO, Director |
NanoViricides |
NanoViricides Management Team Effectiveness
The company has return on total asset (ROA) of (0.3595) % which means that it has lost $0.3595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.579) %, meaning that it created substantial loss on money invested by shareholders. NanoViricides' management efficiency ratios could be used to measure how well NanoViricides manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.49. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, NanoViricides' Total Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 22 M, whereas Non Current Assets Total are forecasted to decline to about 6.7 M.The current year's Common Stock Shares Outstanding is expected to grow to about 14 M, whereas Net Loss is forecasted to decline to (8.1 M).
NanoViricides Workforce Comparison
NanoViricides is rated below average in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 403. NanoViricides claims roughly 7.0 in number of employees contributing just under 2% to equities under Health Care industry.
NanoViricides Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. NanoViricides Price Series Summation is a cross summation of NanoViricides price series and its benchmark/peer.
NanoViricides Notable Stakeholders
A NanoViricides stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NanoViricides often face trade-offs trying to please all of them. NanoViricides' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NanoViricides' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Irach Taraporewala | CEO | Profile | |
| Eugene Seymour | CEO, Director | Profile | |
| Anil Diwan | Chairman and President and Secretary | Profile | |
| Meeta Vyas | Interim CFO | Profile | |
| Stanley Glick | Independent Director | Profile | |
| Milton Boniuk | Independent Director | Profile | |
| Mark Day | Independent Director | Profile | |
| Mukund Kulkarni | Independent Director | Profile | |
| James Sapirstein | Independent Director | Profile | |
| Randall Barton | Chief Officer | Profile | |
| BS MBA | Chief Officer | Profile |
About NanoViricides Management Performance
The success or failure of an entity such as NanoViricides often depends on how effective the management is. NanoViricides management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NanoViricides management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NanoViricides management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.52) | (0.55) |
The data published in NanoViricides' official financial statements usually reflect NanoViricides' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of NanoViricides. For example, before you start analyzing numbers published by NanoViricides accountants, it's critical to develop an understanding of what NanoViricides' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of NanoViricides' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NanoViricides' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in NanoViricides' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NanoViricides. Please utilize our Beneish M Score to check the likelihood of NanoViricides' management manipulating its earnings.
NanoViricides Workforce Analysis
Traditionally, organizations such as NanoViricides use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NanoViricides within its industry.NanoViricides Manpower Efficiency
Return on NanoViricides Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 780.8K | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 719.2K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for NanoViricides Stock analysis
When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is NanoViricides' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Return On Assets (0.36) | Return On Equity (0.58) |
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.